Short-term drop in antibody titer after the third dose of SARS-CoV-2 BNT162b2 vaccine in adults

Jonas Herzberg1*, Bastian Fischer2*, Heiko Becher3, Ann-Kristin Becker, Human Honarpisheh1, Salman Yousuf Guraya4, Tim Strate1, Cornelius Knabbe2

* Shared co-first authorship
1 Department of Surgery – Krankenhaus Reinbek St. Adolf-Stift, Hamburger Strasse 41, 21465 Reinbek, Germany
2 Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum NRW, Georgstraße 11, 32545 Bad Oeynhausen, Germany
3 Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
4 Clinical Sciences Department, College of Medicine, University of Sharjah, P. O. Box 27272 Sharjah, United Arab Emirates

Corresponding Author:
Dr. Jonas Herzberg
Krankenhaus Reinbek St. Adolf-Stift
Department of Surgery
Hamburger Str. 41
21465 Reinbek
Germany
E-Mail: jonas.herzberg@Krankenhaus-Reinbek.de
Tel: +49 40 7280 5375

Keywords:
SARS-CoV-2, humoral and cellular immunity, Health Care worker, Seroprevalence, Vaccination, BNT162b2

Abstract:
Little is known about the longevity of antibodies after a third dose of BNT162b2 (BioNTech/Pfizer).
Therefore, the serum antibody levels were evaluated after the third dose of BNT162b2 which dropped
significantly within 11 weeks from 4155.59 ± 2373.65 BAU/ml to 2389.10 ± 1433.90 BAU/ml, p-value < 0.001 but remained higher than after the second dose.

These data underline the positive effect of third dose of BNT162b2 but shows a rapid and significant drop of antibodies within a short span of time.

**Trial Registration:** This trial was prospectively registered in the German Clinical Trial Register (DRKS00021270).
Introduction

The protective role of SARS-CoV-2 BNT162b2 vaccine, as introduced by BioNTech/Pfizer, has been endorsed by several studies[1,2]. The rapidly increasing number of COVID-19 cases among the previously vaccinated individuals has led to the addition of a third dose of vaccines as a booster [3,4]. The immediate immune response after the third dose has been evaluated by a wide range of clinical trials [5–8]. Till now, there is a lack of best clinical evidence about the durability and long-term impact of the immune response that is invariably induced by the third dose.

Foregoing in view, we assessed the anti-spike-IgG-antibody-titers, 4 and 11 weeks after the third dose of BNT162b2 as well as 11 weeks after the administration of the second dose of BNT162b2 within a previously elaborated study cohort.

Methods

We included employees of the Hospital Reinbek St. Adolf-Stift, a German secondary care hospital to the ProCoV-study, established in April 2020 [9]. In the follow-up analysis, all participants with a homogeneous prime-boost-protocol, who had received three doses of BNT162b2, were invited to participate in this study. Participants with a previous self-reported SARS-CoV-2-infection within the last six months before the last blood drawn were excluded.

All participants provided a blood sample 11 weeks after the second dose of vaccinate and then 4 weeks after the third dose between November and December 2021. Subsequently, in January 2022, a follow-up blood sample was drawn 11 weeks after the third dose.

Anti-SARS-CoV-2-IgG antibodies were measured using the anti-SARS-CoV-2- assay (IgG) from Abbott (Chicago, USA) and the values were quantitatively expressed in binding-antibody-units per ml (BAU/ml) In addition, neutralizing anti-SARS-CoV-2 antibodies were detected using the NeutraLISA™ SARS-CoV-2 Neutralization Antibody Detection KIT (Euroimmun, Lübeck, Germany).

The study was approved in April 2020 by the ethics committee of the medical association Schleswig-Holstein, Germany and all participants provided written and informed consent prior to inclusion.

The statistical analysis was done using the IBM SPSS Statistics Version 25 (IBM Co., Armonk, NY, USA) and GraphPad Prism 9.

All variables were presented as means with standard deviation and medians with interquartile range. Categorical variables were shown as numbers with percentages. The differences between groups were analyzed using the Wilcoxon test. A *p*-value < 0.05 was considered statistically significant.
Results

Overall, 53 participants fulfilled the inclusion criteria, of which 103 provided a blood sample 11 weeks after the third dose. Six participants were excluded from this cohort due to a reported SARS-CoV-2 infection within the last six months. The characteristics of the recruited 97 participants are shown in Table 1.

Table 1.

Table 1: Baseline characteristics of the study cohort (N = 97)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Mean ± SD</th>
<th>Median</th>
<th>IQR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (M ± SD) [years]</strong></td>
<td>48.03 ± 9.45</td>
<td>48.00</td>
<td>15</td>
</tr>
<tr>
<td><strong>BMI (M ± SD) [kg/m²]</strong></td>
<td>25.61 ± 4.71</td>
<td>24.69</td>
<td>6.16</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td>N (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women (%)</td>
<td>73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (%)</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immunglobolin G</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A1: 11 weeks after second dose [BAU/ml]</td>
<td>611.92 ± 450.31</td>
<td>543.60</td>
<td>599.90</td>
</tr>
<tr>
<td>B1: 4 weeks after third dose [BAU/ml]</td>
<td>4155.59 ± 2373.65</td>
<td>3482.70</td>
<td>3200.80</td>
</tr>
<tr>
<td>C1: 11 weeks after third dose [BAU/ml]</td>
<td>2389.10 ± 1433.90</td>
<td>1949.90</td>
<td>1921.40</td>
</tr>
<tr>
<td>Difference C1-A1</td>
<td>1777.18 ± 1470.51</td>
<td>1466.80</td>
<td>2075.00</td>
</tr>
<tr>
<td>Difference C1-B1</td>
<td>-1766.49 ± 1329.81</td>
<td>-1574.60</td>
<td>1440.05</td>
</tr>
<tr>
<td><strong>Neutralizing antibodies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2: 11 weeks after second dose [%]</td>
<td>83.26 ± 27.79</td>
<td>97.23</td>
<td>14.80</td>
</tr>
<tr>
<td>B2: 4 weeks after third dose [%]</td>
<td>99.73 ± 0.18</td>
<td>99.76</td>
<td>0.10</td>
</tr>
<tr>
<td>C2: 11 weeks after third dose [%]</td>
<td>99.51 ± 0.64</td>
<td>99.69</td>
<td>0.23</td>
</tr>
<tr>
<td>Difference C2-A2</td>
<td>16.25 ± 27.61</td>
<td>2.29</td>
<td>14.95</td>
</tr>
<tr>
<td>Difference C2-B2</td>
<td>-0.22 ± 0.51</td>
<td>-0.10</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td>N (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac (%)</td>
<td>20 (20.62)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary (%)</td>
<td>9 (9.28)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic (%)</td>
<td>18 (18.56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunologic (%)</td>
<td>1 (1.03)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (%)</td>
<td>18 (18.56)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Smoking (%)</strong></td>
<td>25 (25.77)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

M: mean
IQR: Interquartile range
SD: standard deviation
Later, 11 weeks after the second dose, 93 participants (95.9%) showed a positive antibody response with a mean titer of $611.92 \pm 450.31$ BAU/ml. Four weeks after the third dose, all participants showed a seropositive result and remained seropositive 11 weeks after the third dose.

A comparison of the antibody titer 11 weeks after second dose with those 11 weeks after the third dose showed a significant rise in antibody titer that was induced by the third dose ($611.92 \pm 450.31$ vs. $2389.10 \pm 1433.90$, $p$-value < 0.001). A corresponding rise in the neutralizing antibodies (83.26 ± 27.79 vs. 99.51 ± 0.64, $p$-value < 0.001) was also reported.

Interestingly, the mean IgG-titer four weeks after the third dose was found to be $4155.59 \pm 2373.65$ BAU/ml which dropped significantly to $2389.10 \pm 1433.90$ BAU/ml 11 weeks after the third dose ($p$-value < 0.001) (Figure 1A). This drop was also noted in the neutralizing antibodies titer, which also showed a significant decrease in the weeks after the third dose but remained at a high level (99.73% ± 0.18% vs. 99.51, $p$-value < 0.001) (Figure 1B).

Figure 1: The vaccine induced serological immune response at different timepoints post second- and third doses of BNT162b2. A: Anti-SARS-CoV-2-IgG at different timepoints (left: 11 weeks post second vaccine dose, right: 4- and 11 weeks after third vaccine dose, respectively). B: Binding inhibition at
different timepoints (left: 11 weeks post second vaccine dose, right: 4- and 11 weeks after third vaccine dose, respectively). Horizontal lines within plotted data show the median (red line) and interquartile ranges. ****p < 0.0001 (Mann-Whitney U-test).

Discussion

Our study demonstrates a significant rise in the binding-antibody titer and the neutralizing antibodies following the third dose as compares to the serological response to the second dose of BNT162b2.

On the other hand, our data has reported a rapid and significant drop in the binding-antibody titers and neutralizing antibodies in a short term (within 7 weeks) after third vaccination, though the titers remain high.

Till now, little is known about the sustained and long-term impact of the vaccination-induced immune response. Despite a small cohort size of our study, several other studies have shown positive inductive immunological effect of a third dose of BNT162b2 [5,6,8]. Our study provides an original clinical data about the antibody persistence of the second- and third dose during a short-term follow-up. While persistence of the humoral immunity is much stronger after the administration of the third dose of BNT162b2, the dropping antibody titers following the third dose signals the potential indication of a fourth dose of vaccine. This possibility has been recently suggested by some recent reports [10,11].

Limitations

This study is limited by a small sample size and by the lack of cellular immunity testing. Further studies are needed to evaluate the infection rate depending on several antibody titers which can detect potential measurable thresholds.

Conclusion

This cohort study provides first human-based clinical data about the longevity of the humoral immune response induced by a third dose of BNT162b2 against COVID-19. This data may potentially facilitate to determine the indication of an additional fourth dose of anti-COVID-19-vaccine.
References


10. Standing Committee on Vaccination. Press release STIKO [Internet].